海思科(002653.SZ)：1类创新药安瑞克芬注射液新适应症获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for its innovative drug, HSK21542, which is expected to provide better options for patients suffering from itching [1] Company Summary - HSK21542, marketed as Anruikefen Injection (brand name: Sishujing), is a highly selective peripheral kappa opioid receptor agonist developed independently by the company [1] - Clinical research indicates that HSK21542 significantly alleviates itching, with both primary and secondary efficacy indicators showing substantial improvement over the placebo group [1] - The safety profile of HSK21542 injection is reported to be good and controllable [1] Industry Summary - The newly approved indication for HSK21542 will be included in the priority review and approval process in July 2024, highlighting the drug's potential impact on the market [1] - The approval of HSK21542 is expected to enhance treatment options for patients, indicating a positive development in the pharmaceutical industry focused on innovative therapies [1]